Molecular diagnosis of Burkitt's lymphoma.
By S. Dave, K. Fu, George W. Wright, L. Lam, P. Kluin, Evert-Jan G. Boerma, T. Greiner, D. Weisenburger, Andreas Rosenwald, G. Ott and 28 more. New England Journal of Medicine, 2006
1,004 citations recorded by the source corpus.
Subfields: Neurology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/cc1ae0da910b76e1fe0dfccd7ce1969624977ec2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012, methodology): “‡In training set, cell-of-origin distinctions were assigned according to GEP and signatures previously described by Wright et al(25) and Dave et al.(24) §In validation set, cell-of-origin distinctions were assigned according to immunohistochemical algorithm reported by Choi et al.”
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. (2011, background): “One study found the molecular signature of BL (mBL) in a group of cases diagnosed as DLBCL or high grade B-cell lymphomas.(103) In spite of the mBL signature these cases differed clinically and genetically from classical BL.”
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications (2020, background): “and GCB-4, defined as the subset of genes characteristically expressed in normal GC B cells that are expressed more highly in BL than in DLBCL (Dave et al., 2006) (Table S4).”
- Human disease classification in the postgenomic era: A complex systems approach to human pathobiology (2007, background): “Subcategorizing histologically similar cancers by differences in surface biomarkers, transcription profiling, or proteomic analysis is currently being applied to several malignancies, including lymphomas”
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research (2009, neutral): “Diffuse areas in any Grade 3 FL should be designated as DLBCL (with FL) and are more commonly observed in Grade 3B.62 Further studies are likely to lead to more precise delineation of the Grade 3 cases truly belonging within FL and those representing an intrafollicular variant of the GCB type of DLB”
- The genetic landscape of mutations in Burkitt lymphoma (2012, background): “Whereas gene expression profiles of Burkitt lymphoma and the more common DLBCL have shown that these two diseases have vast molecular differences 1,3 , the genetic underpinnings of these differences are not known.”